Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 7/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.35 |
| ▸ | SHBG | P04278 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452488 | 1.00 | AR (0.78) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL3452309 | 1.00 | AR (0.78) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL3452180 | 1.00 | AR (0.78) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL5030906 | 1.00 | AR (0.78) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL25863600 | 0.99 | AR (0.77) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL4232069 | 0.93 | AR (0.67) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL4215627 | 0.93 | AR (0.67) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL4215614 | 0.93 | AR (0.67) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL4225224 | 0.93 | AR (0.67) | ARLMNAMAPTPGRNR3C1 | |
| SCHEMBL5028679 | 0.93 | AR (0.67) | ARLMNAMAPTPGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | AR 7/4885LMNA 388/4885MAPT 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.